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OPERATIONS AND ECONOMICS IN A PANDEMIC

The Resilience of Radiation Oncology in the
COVID Era and Beyond
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Introduction

Impact of Pandemic on Cancer Care

The COVID-19 pandemic has dramatically and permanently disrupted global life. Hospitals throughout the
world have experienced a surge of COVID-19 cases,
requiring the rapid expansion of hospital capacity and
redeployment of medical staff. Moreover, the widespread closure of nonessential businesses has led to
record unemployment and a global economic downturn.
As of this writing, our employer, Northwell Health in
New York State, has diagnosed over 40,000 COVID-19
patients and had greater than 18,000 COVID admissions
across our 19 hospitals.1 As a result, routine ambulatory
medical care has slowed considerably, with a collateral
impact on general health that will be significant and
long lasting.
In this manuscript, we outline our thesis regarding the
pandemic’s effects on our specialty. First, we believe that
radiation oncology will prove clinically resilient with a
potential expanding role in cancer management. Second,
we are concerned about access to cancer care for reasons
that include but are not limited to patients’ hesitance to
interact with health care staff, delays in cancer screening
and surgery, and financial limitations related to patient
insurance coverage and the financial instability of radiation
practices themselves. Third, we believe that the pandemic
will drive rapid adoption of technology and innovations
that improve access to cancer care.

Just a few months ago, we were celebrating encouraging
news about declining cancer death rates in the United
States. From 2008 to 2018, the death rate for all cancers
decreased annually by about 1.4% in females and 1.8% in
males.2 The driver of that success was a combination of
factors including prevention, screening, and treatment,
representing a massive effort of health policy and advances
in therapy. Despite these gains, estimated cancer deaths this
year will exceed 600,000 individuals and will sit alongside
cardiovascular diseases as the top 2 causes of death in the
United States.
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Decline in cancer clinic visits, screening, and
diagnosis
On March 11, the World Health Organization declared
COVID-19 a pandemic; on or around March 13, 2020,
hospitals nationally started cancelling elective surgical and
interventional procedures. Outpatient radiology and
endoscopy suites closed. The impact of the pandemic on
cancer care was immediate. Community cancer practices
saw a 40% decline in new patients between February and
April of 2020, with an associated 17% decline in chemotherapy use and up to an 80% rate of cancellation or noshows for follow-up visits.3 Additionally, in March 2020
there was a precipitous drop in cancer screenings by as
much as 94% for colon, cervix, and breast cancers.4
Disclosures: none.

Volume 108  Number 2  2020

Patient fears and financial concerns
Communities throughout the country implemented strict
stay at home and social distancing policies. As the
pandemic spread, we learned that older patients with
comorbidities were at greatest risk of complications due to
COVID-19.1 The general public, including patients with
cancer, understandably has become fearful of visiting
hospitals and clinics for medical care.
Beyond the effects of COVID-19 on patients’ willingness to interact with health care settings, unprecedented
unemployment will place added stress on oncology practices by shifting insurance coverage to exchange products
or Medicaid, which have lower reimbursement rates. A
shift in payer mix will undoubtedly reduce medical practice
incomes. Furthermore, unemployed patients may be unable
to afford out-of-pocket costs. In 1 survey of over 1200
patients with cancer conducted by the American Cancer
Society, 38% of respondents reported an impact of the
COVID-19 pandemic on their ability to pay for care.5 An
update of this survey found that 46% of respondents reported a change to their financial situation that affected
their ability to pay for care,6 23% are worried about losing
health insurance, and 32% are worried about affording
basic household expenses. The combination of patient fear
and the financial toxicity of health care will contribute
further to the delay of patients seeking cancer screening and
cancer care.

Impact of delays in care
The impact of delayed cancer care is difficult to estimate.
One study that attempted to calculate the impact of surgical
cancellations found that 3- and 6-month delays in cancer
surgery were associated with 5% and 11% increases in
cancer deaths, respectively.7 Delays in diagnosis and timely
treatment may lead to stage migration and ultimately lower
rates of cancer cure.8 Dr Ned Sharpless, director of the
National Cancer Institute, recently expressed concerns that
“in 2021 or 2022 or 2023, we will have the first Annual
Report to the Nation since 1993 that shows an increase in
cancer mortality.”9

Immediate Impact of Pandemic on Radiation
Oncology
Having worked through the New York surge of COVID-19
in March and April 2020, we have learned that radiation
oncology is resilient relative to surgery and chemotherapy.
Throughout this crisis, our radiation medicine department
has consistently maintained safe, timely, and evidencebased standards of care with a very low staff and patient
infection rate. As described earlier, surgery was all but shut
down for 2 months. Systemic chemotherapy remains
available, but multiple reports now show an increased risk
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of death from coronavirus among patients who traditionally
receive more aggressive chemotherapy,10 including those
with hematologic cancers,11 lung cancer, and metastatic
cancer.12 Targeted therapies and immune checkpoint inhibitors do not appear to be associated with higher risk of
death.13 Radiation therapy for solid tumors has not been
shown to increase a patient’s risk of dying from
coronavirus.

Standard fractionation remains our preferred
evidence-based approach
Early in the pandemic, a number of organizations published
disease-specific guidelines for radiation therapy practice
modifications in the midst of this pandemic.14 Hypofractionation and decreased use of concurrent radiosensitizing chemotherapy were the focus of many of these
reports. As we enter the third month of this pandemic, we
have found that most patients can be safely treated with
standard-of-care radiation fractionation, especially in diseases for which evidence-based use of hypofractionated
regimens for curative intent do not exist. For example, most
aerodigestive tract head and neck cancers require standard
fractionation to doses between 60 and 70 Gy for cure, with
concurrent chemotherapy. We believe that standard fractionation should continue in the appropriate patient populations wherever possible. One exception may be in lung
cancer; several reports indicate increased mortality from
COVID-19 in this patient population, and a change in
practice to reducing the length of treatment may be
beneficial.15
Where there is a high level of evidence for hypofractionation in other common disease sites, including
prostate, breast, and glioblastoma, we continue to
frequently employ hypofractionation, as we have previously published.16 In our experience, there is a very low
rate of COVID-19 in patients undergoing weeks of radiation therapy, provided they are following recommendations
for mask-wearing, hand hygiene, and physical distancing.
Likewise, we have not seen any nosocomial spread despite
treating COVID-19epositive patients.

Radiation prevails when hospital resources are
limited
Rescheduling of delayed screenings and surgery will likely
take many months, if not longer, to catch up, because
ambulatory health care was operating at near-capacity
before COVID-19. In an effort to triage this backlog,
multidisciplinary management can guide patients toward
radiation therapy for diseases where outcomes of radiation
are equivalent to surgery. For example, radiation alone is
appropriate for prostate and early-stage oropharynx cancers. Redirecting patients to radiation therapy will free up
surgical capacity for malignancies such as colon cancer and
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melanomas that are surgically cured without acceptable
nonsurgical alternatives.
To operationalize this type of decision-making, we
would suggest a 3-dimensional multidisciplinary approach
to cancer treatment decisions, where unbiased leaders can
take into account the patient queue and resource availability
to facilitate optimal clinical outcomes (Fig. 1). The usual
division of cancer into disease teams for multidisciplinary
treatment decision-making is helpful and necessary, but it
loses the broader perspective of resource availability within
the health care entity. As surgery reopens, triage of the
extensive backlog requires high-level awareness of available resources. Although we believe this “Resource-Allocating Multidisciplinary Approach” would be effective, we
are realistic in noting that traditional issues of politics and
turf within the house of medicine could prevent this
model’s success. Nevertheless, if resources were to become
severely limited, we believe this approach could have the
greatest effect on the outcome of a large population of
patients with cancer, rather than just the patient at hand.

Preparing for a value-based future helps weather
the COVID-19 crisis
Over the past decade, our department has instituted systems
and standards to prepare for a value-based future of health
care.17,18 These include our centralized cloud-based treatment planning, remote access to programs for all physicians and physicists, evidence-based and consensus-driven
treatment directives,19 an electronic whiteboard,20 and
other processes to improve safety21 and efficiency.22,23 This
structure created standards and expectations of the staff and
an operating culture that served as the foundation during
the current crisis (Fig. 2). Our crisis management team
could then focus on instituting pandemic-related policies,
including universal masking, screening for symptoms by

phone and in person at each reception desk, cleaning routines, telehealth, and expanded work from home. Our
culture of safety and teamwork allowed staff to focus on
high-quality patient care.

Communicating with patients
Telemedicine has proven its value during this crisis, and we
would not be the first or last to suggest that it will have a
permanent place in radiation oncology. Although we
believe there is value to a face-to-face interaction with our
patients, radiation oncology uniquely requires in-office
patient presence for treatment simulation, thus allowing a
virtual consultation as an introduction and the presimulation office visit as a built-in opportunity to address
questions and to review the care plan. An added benefit of
telehealth includes the participation of other colleagues as
part of a multidisciplinary consult or inclusion of other
family members from other parts of the country. There is
still much to learn; techniques for making the most of
telehealth, and establishing protocols for various cancers,
are necessary to correctly assess our patients’ needs. Our
department has created telehealth protocols encompassing
all cancer diagnoses and types of visits (manuscript
submitted).
Market research has demonstrated that patients are
currently reticent about interfacing with health care settings
(unpublished data). Some of this change in attitude may be
transient, but it remains paramount that we share our experiences of safe cancer care to help allay these fears.
Assurances that we have created a safe environment (with
universal masking, physical distancing, abundant hand
sanitizer, and frequent cleanings) has in a way redefined the
definition of “safety” in our departments, where we
generally think of risk associated with clinical treatment
errors. Establishing new metrics for quality of radiation
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Fig. 1. Traditional model of multidisciplinary cancer management layered with the additional dimension of resource
allocation as a driver for treatment selection.
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oncology care, such as rate of emergency room visits and
hospitalizations during treatment that result from hypermanagement of our patients, will be key toward establishing patient trust. Another quality indicator could be the
number of staff interactions associated with an office visit.
Finally, basic metrics such as wait times become all the
more meaningful in this new environment.

What Is the Future of US Health Care Under
COVID-19?
Health care at the end of 2020 and beyond will look
significantly different than it did at the end of 2019. Until a
vaccine is developed and widely implemented, COVID-19
modeling shows several waves of viral persistence for some
time to come,24 occupying both inpatient and outpatient
resources across all of health care. We believe that radiation
oncology and health care will see permanent changes as a
result of this pandemic.

Radiation oncology must recommit to high value
care
In the long term, we believe that radiation oncology is
clinically resilient to COVID-19. We will continue to offer
patients access to modern, uncompromised, evidence-based
cancer care. In the short term, radiation oncology practices
face significant financial risks associated with the slowing
of new patient referrals secondary to lower cancer
screening and surgery.
From a high-level perspective, the COVID-19 crisis has
laid bare the frailties of the US health care system that will
have a direct impact on radiation oncology practices.
Specifically, we will see financial instability25,26 for practices caused by (1) delays in cancer diagnosis and treatment, (2) drastically reduced referrals, and (3) insurance
shifts toward public payers. This loss of revenue, along
with the macrolevel competition for capital throughout the
health care system, will translate into fewer opportunities
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for oncology practices to make large investments. Looking
ahead, there will be a need for fair and balanced resource
allocation for both COVID-19 and routine health care
(which includes screening and treatment of cancer).
The typical business model of capital expense depreciated over time represents a vulnerability to radiation
oncology. Our machines are expensive. Medical oncology,
on the other hand, has minimal capital investment requirements for infusion chairs and chemotherapy is
reimbursed for each administered treatment without
upfront capital. Given the new economic realities we will
all be facing, we believe this pandemic presents an opportunity for our field to fully commit to the concept of
high-value radiation oncology care.27 We must reconsider
the marginal benefits of expensive technologies, including
proton beam therapy and magnetic resonance imaging
linear accelerators. High-value care requires that we stop
the “technology arms race” under the guise of improved
outcomesdunless and until trial data clearly identify the
value of these tools. We should redirect funds and resources to other areas of our practice where they make
more of an impact. Our time is better spent advocating for
innovations in care delivery that maximize value. For
example, after years of failed efforts, we should collectively develop policies that direct our vendors to establish
interoperability requirements for the equipment and software that will tangibly lead to higher quality, efficiencies,
and above all, enhanced safety. Likewise, technologies
such as autosegmentation and AI-based planning software
will likely prevail as winners.

Health care is at a turning point
We foresee the COVID-19 crisis creating a deeper divide in
the US 2-tiered system of cancer care. Population-level
cancer mortality will rise, while pockets of excellent care
will continue to reflect the best cancer care available anywhere in the world. Despite the COVID-19 crisis bringing
these inequalities to the front of our minds, we do not see
any short-term plans for our nation to address health care
disparities in a meaningful way. How much will our disease
outcomes have to worsen before we make structural
changes?
Out of the depths, the phoenix will rise. We foresee rapid
technological adoption and innovation across the health
care continuum. Technology enhances access. The
pandemic has proven the value of technology in our personal lives, allowing us to successfully work from home,
order food and groceries, and connect with colleagues
around the world. We have seen technology’s positive
impact in telemedicine as the primary and most obvious
change and in virtual care tools such as mobile patientreported outcome and symptom management applications.
Technology also helps physicians access each other,
through virtual tumor boards, conferences, websites, and
social media that allow geographically dispersed clinicians
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to seek their colleagues’ expertise. We have already seen in
our own multidisciplinary cancer center, for example, that
work from home and video-conferencing platforms have
enabled easier collaborative evaluation of imaging studies
between physically distant physicians.
We believe that this pandemic will only further accelerate the rapid adoption of technology into health care.
Health care has been operating in an analog era, with
overreliance on in-person patient management and physician conferences and tumor boards. With the adoption of
tech into health care, the natural outcome is new models of
care. For example, patients can consult clinicians anywhere
in the country; physicians can then connect with one
another, and that patient’s care can be delivered locally
without ever physically meeting the prescribing or treating
doctor.
We also anticipate that technology adoption will force
new payment models. The Center for Medicare and
Medicaid Services has already significantly modified payments for evaluation and management visits to facilitate
telemedicine. CMS and commercial payers should similarly
appreciate the role of virtual nonaudio/video care in highvalue medicine. Payers would be wise to incorporate techenabled virtual patient management, virtual tumor boards
and conferences, and physician-to-physician “telemedicine” in their payment structures. Virtual care allows patients anywhere to have access to expert clinicians,
ancillary staff, evidence-based guidelines for care and
efficient systems that have worked in specific centers. In
addition, virtual care allows greater access to clinical trials
that are currently unavailable to the vast majority of
Americans.
We believe that technology-enabled patient care and
clinician communication can improve access to all forms of
medical care, including radiation therapy. We have a moral
imperative to come out of this crisis with innovative ways
of improving the glaring disparities in health care in this
country. Will our specialty remain complacent with the
status quo of access to radiation therapy, where low-income
inner-city and rural communities have disproportionally
less access to care and significantly worse outcomes? Will
we stay silent amid a 2-tiered health system where city- and
state-run systems cannot afford the basic technology requirements needed to meet certain standards of care? The
lack of innovation with regard to care delivery perpetuates
inequalities and a system where some patients are only
offered outdated forms of cancer care.
The unknowns still remain. As in other times of crisis,
larger health systems are more likely to weather the
financial setbacks and emerge stronger in the long run. Will
there be further health care market consolidation under the
umbrella of large health care entities or private equity
firms? How many Americans will lose access to employerbased health insurance? Furthermore, how will the nationwide lockdown and lack of recreational arenas affect the
general health of populations? Will we see an increase in
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diseases associated with sedentary lifestyles? What will be
the impact on mental health?28

Conclusions
The COVID-19 pandemic will have a long-lasting effect on
cancer care. In the immediate short term, we must inspire
confidence in our patients that health care is safe and that
they continue with routine care, including health screenings. Although the immediate crisis management discussions in radiation oncology revolved around how to shorten
treatment courses, we now appreciate that such compromises are not necessary. Standard evidence-based care
outside of clinical trials can be used safely without the need
to improvise new treatments. Radiation oncology is well
positioned to continue curative care and to help load balance when considering health care resource limitations. Our
participation at multidisciplinary conferences, advocating
for the opportunity that our specialty provides for safe
treatments, is vital if we are to maintain the success of
lower cancer mortality over time. This pandemic has
revealed major shortcomings in our public health infrastructure and health care at large. We have a responsibility
as a specialty to think big. We must innovate so that cancer
care and radiation therapy in particular remain widely
available and accessible.
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